常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.03/-0.23
|
|
企業價值
678.79M
|
| 資產負債 |
|
每股賬面淨值
-0.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
33.28M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |

7.46 
